Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)

NCT03843125 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03843125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03843125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
September 9, 2019
Completion date
April 1, 2022
Enrollment
1,147 (actual)
Sites
297

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus